Skip to main content
PMC home page

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

bioRxiv logoLink to bioRxiv
[Preprint]. 2023 Aug 22:2023.08.17.553767. [Version 1] doi: 10.1101/2023.08.17.553767

Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity

Alberto Moreno, Kelly Manning, Maryam I Azeem, Ajay K Nooka, Madison Ellis, Renee Julia Manalo, Jeffrey M Switchenko, Bushra Wali, Jonathan L Kaufman, Craig C Hofmeister, Nisha S Joseph, Sagar Lonial, Kavita M Dhodapkar, Madhav V Dhodapkar, Mehul S Suthar
PMCID: PMC10473610  PMID: 37662390

ABSTRACT

We characterized virus-neutralization and spike-binding antibody profiles in myeloma patients following monovalent or bivalent-SARS-CoV-2 booster vaccination. Vaccination improves the breadth of binding antibodies but not neutralization activity against current variants. Hybrid immunity and immune imprinting impact vaccine-elicited immunity.

Full Text Availability

The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.

Articles from bioRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES